Quarterly report pursuant to Section 13 or 15(d)

Share-Based Compensation

v3.23.2
Share-Based Compensation
9 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation

7. Share-Based Compensation

 

In April 2020, the Company adopted the 2020 Omnibus Equity Incentive Plan (the “Plan”). On January 1, 2023, the total number of shares authorized under the Plan increased to 318,561. There were 318,561 shares available for issuance under the Plan as of June 30, 2023. The Plan increases the amount of shares issuable under the Plan by four percent of the outstanding shares of common stock at each January 1, each year. The Plan permits the granting of share-based awards, including stock options, restricted stock units and awards, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the Plan. The terms of the awards are determined by the Company’s Board of Directors.

 

Restricted stock units

 

In July of 2020, 46,703 restricted stock units (“RSUs”) were granted, 50% of which vested on April 2, 2021 and the remaining 50% vested on April 2, 2022. In March of 2021, an additional 3,357 RSUs were granted, 50% of which vested on March 25, 2022 and the remaining 50% vested on March 25, 2023. In December of 2021, 46,478 RSUs were granted, 100% of which vested on January 1, 2023. In December of 2022, 172,672 RSUs were granted, 100% of which vest on January 1, 2024.

 

In January 2023, 121,366 of the RSUs granted in December 2022 were cancelled and subsequently reissued as restricted shares of the Company’s common stock (“Restricted Stock Awards” or “RSAs”). The RSAs have the same vesting conditions as the original RSUs issued in December 2022. The Company accounted for this as a stock compensation modification resulting in $38,837 of incremental expense which will be recognized over the remaining vesting period.

 

Any unvested RSUs or RSAs will be forfeited upon termination of services. The fair value of an RSU or RSA is equal to the fair market value of the Company’s common stock on the date of grant. RSU and RSA expense is amortized straight-line over the vesting period.

 

 

Sonnet BioTherapeutics Holdings, Inc.

Notes to Unaudited Interim Consolidated Financial Statements

 

The Company recorded share-based compensation expense associated with the RSUs and RSAs in its accompanying unaudited interim consolidated statements of operations as follows:

 

   

Three Months Ended

    Nine Months Ended     Three Months Ended     Nine Months Ended  
    June 30, 2023     June 30, 2023     June 30, 2022     June 30, 2022  
Research and development   $ 24,554     $ 102,807     $ 64,476     $ 394,558  
General and administrative     25,451       95,813       43,416       396,300  
Share Based Compensation   $ 50,005     $ 198,620     $ 107,892     $ 790,858  

 

The following table summarizes RSU activity under the Plan:

 

    RSU     Weighted Average Grant Date Fair Value  
Unvested balance at October 1, 2022     47,798     $ 7.89  
Granted     172,672     $ 0.98  
Vested     (47,803 )   $ 0.57  
Forfeited/cancelled     (121,366 )   $ 0.97  
Unvested balance at June 30, 2023     51,301     $ 0.54  

 

As of June 30, 2023, total unrecognized compensation expense relating to unvested RSUs granted was $24,389, which is expected to be recognized over a weighted-average period of less than one year.

 

The following table summarizes RSA activity under the Plan:

 

    RSA     Weighted Average Grant Date Fair Value  
Unvested balance at October 1, 2022         $  
Granted     121,366     $ 1.29  
Vested         $  
Forfeited/cancelled         $  
Unvested balance at June 30, 2023     121,366     $ 1.29  

 

As of June 30, 2023, total unrecognized compensation expense relating to unvested RSUs granted was $75,623, which is expected to be recognized over a weighted-average period of less than one year.